Triple-negative (TN) and basal-like (BL) breast cancer definitions have been used interchangeably to identify breast cancers that lack expression of the hormone receptors and overexpression and/or amplification of HER2. However, both classifications show substantial discordance rates when compared to each other. Here, we molecularly characterize TN tumors and BL tumors, comparing and contrasting the results in terms of common patterns and distinct patterns for each. In total, when testing 412 TN and 473 BL tumors, 21.4% and 31.5% were identified as non-BL and non-TN, respectively. TN tumors identified as luminal or HER2-enriched (HER2E) showed undistinguishable overall gene expression profiles when compared versus luminal or HER2E tumors th...
Distinct subtypes of triple negative (TN) breast cancer have been identified by tumor expression pro...
Triple-negative breast cancers (TNBC) neither express hormone receptors, nor overexpress HER2. They ...
PURPOSE: Despite the availability of current standards of care treatments for triple negative breast...
Triple-negative (TN) and basal-like (BL) breast cancer definitions have been used interchangeably to...
Purpose: Triple-negative (TN; estrogen receptor, progesterone receptor, and HER-2 negative) cancer a...
Objective. Triple-negative breast cancer (TNBC) accounts for 15–25% of breast cancers. It is increas...
Background: Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor (ER)...
Triple-negative breast cancer (TNBC) is a heterogenous disease. For personalized medicine, it is ess...
Triple negative breast cancer (TNBC) is a subtype of breast cancer (BC) with a heterogeneous nature ...
Triple-negative breast cancers (TNBCs) are a diverse and heterogeneous group of tumors that by defin...
Breast cancer is a highly heterogeneous disease with differences in histopathological and biological...
Molecular classification of breast cancer (BC) identified diverse subgroups that encompass distinct ...
BRCA1-mutated breast cancer is associated with basal-like disease; however, it is currently unclear ...
Triple-negative breast cancer (TNBC) is characterized by the absence of expression of the estrogen r...
AbstractTriple negative breast cancer (TNBC) is a subtype of breast cancer (BC) with a heterogeneous...
Distinct subtypes of triple negative (TN) breast cancer have been identified by tumor expression pro...
Triple-negative breast cancers (TNBC) neither express hormone receptors, nor overexpress HER2. They ...
PURPOSE: Despite the availability of current standards of care treatments for triple negative breast...
Triple-negative (TN) and basal-like (BL) breast cancer definitions have been used interchangeably to...
Purpose: Triple-negative (TN; estrogen receptor, progesterone receptor, and HER-2 negative) cancer a...
Objective. Triple-negative breast cancer (TNBC) accounts for 15–25% of breast cancers. It is increas...
Background: Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor (ER)...
Triple-negative breast cancer (TNBC) is a heterogenous disease. For personalized medicine, it is ess...
Triple negative breast cancer (TNBC) is a subtype of breast cancer (BC) with a heterogeneous nature ...
Triple-negative breast cancers (TNBCs) are a diverse and heterogeneous group of tumors that by defin...
Breast cancer is a highly heterogeneous disease with differences in histopathological and biological...
Molecular classification of breast cancer (BC) identified diverse subgroups that encompass distinct ...
BRCA1-mutated breast cancer is associated with basal-like disease; however, it is currently unclear ...
Triple-negative breast cancer (TNBC) is characterized by the absence of expression of the estrogen r...
AbstractTriple negative breast cancer (TNBC) is a subtype of breast cancer (BC) with a heterogeneous...
Distinct subtypes of triple negative (TN) breast cancer have been identified by tumor expression pro...
Triple-negative breast cancers (TNBC) neither express hormone receptors, nor overexpress HER2. They ...
PURPOSE: Despite the availability of current standards of care treatments for triple negative breast...